Conbercept
Protein / enzyme biologic targets PGF, VEGFA, VEGFB, VEGFC via inhibition
Trials 35 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT07133438 Background | Aug 2025 → May 2027 expected | retinal vein occlusion | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT02577107 Comparator | Jan → Jul 2016 | age-related macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07144865 Comparator | Dec 2024 → Apr 2025 | proliferative diabetic retinopathy | Bojie Hu | Completed | No outcome recorded |
| — | NCT05728476 Comparator | Mar 2024 → Sep 2025 overdue | diabetic macular edema | Tianjin Medical University Eye Hospital | Recruiting | No outcome recorded |
| — | NCT04627402 Background | Nov 2020 → Jun 2021 | diabetic macular edema, type 2 diabetes mellitus | Zhongshan Ophthalmic Center, Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conbercept | “This study compares the effectiveness of Conbercept and Aflibercept in treating neovascular age-related macular degeneration (nAMD).” PMID 38796619 ↗ May 202435“intravitreal injections of conbercept 0.5 mg initially once a month for 3 months, followed by on-demand therapy” NCT07133438 ↗ “Conbercept (KH902) is a newly developed anti-VEGF drug and has been applied in clinic.” NCT03506750 ↗ “intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,” NCT03971162 ↗ “Conbercept or other anti-VEGF drugs” NCT04380974 ↗ |
| Known as | Conbercept Ophthalmic Injection | “Drug: Conbercept Ophthalmic Injection” NCT03223714 ↗ |
| Known as | KH902 | “The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein.” NCT01436864 ↗4“Conbercept (KH902) is a newly developed anti-VEGF drug and has been applied in clinic.” NCT03506750 ↗ |
| Known as | Recombinant Human VEGF Receptor-Fc Fusion Protein | “The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein.” NCT01324869 ↗2“The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein.” NCT01157715 ↗ “The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein.” NCT01436864 ↗ |
| Action | Inhibit | “KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF.” NCT01157715 ↗4“Vascular endothelial growth factor C inhibitor” CHEMBL2108313 ↗ “Vascular endothelial growth factor B inhibitor” CHEMBL2108313 ↗ “Vascular endothelial growth factor A inhibitor” CHEMBL2108313 ↗ “Placenta growth factor inhibitor” CHEMBL2108313 ↗ |
| Modality | Protein / enzyme biologic | “The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein.” NCT01157715 ↗ |
| Route | Intravitreal | “monthly intravitreal injections of 0.5 mg KH902” NCT01157715 ↗ |
| Target | PGF | “Placenta growth factor inhibitor” CHEMBL2108313 ↗ |
| Target | VEGFA | “Vascular endothelial growth factor A inhibitor” CHEMBL2108313 ↗ |
| Target | VEGFB | “Vascular endothelial growth factor B inhibitor” CHEMBL2108313 ↗ |
| Target | VEGFC | “Vascular endothelial growth factor C inhibitor” CHEMBL2108313 ↗ |